The following table presents the reconciliation of non-GAAP to GAAP financial metrics:
|Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA Loss|
|Three Months Ended March 31,||Year Ending December 31, 2013|
|GAAP Net Loss||$ (39.8)||$ (24.0)||$(195.0) - $(170.0)|
|Interest expense, net||1.0||1.4||0.7|
|Benefit from Income taxes||(4.7)||--||(14.6)|
|EBITDA Loss||(34.8)||(6.0)||(173.4) - (148.4)|
|Stock-based compensation expense||11.6||11.1||70.0|
|Contingent consideration expense||(1)||4.8||(5.2)||18.0|
|Debt conversion expense||(2)||10.4||--||10.4|
|Non-GAAP Adjusted EBITDA Loss||$ (8.0)||$ (0.1)||$(75.0) - $(50.0)|
|(1) Represents the expense in the fair value of contingent acquisition consideration payable for the period. The change in the current quarter reflects changes in estimated probabilities and timing of achieving certain developmental milestones.|
|(2) Represents debt conversion expense associated with the early conversion of a portion of our 2017 convertible notes in March 2013.|
BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future. Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV